Sign In
Buy ZVRA
$13.00
+0.350 (+2.77%)
At Close: Jun 23, 2026
Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD
07:30am, Tuesday, 02'nd Dec 2025
CELEBRATION, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with
Zevra Therapeutics, Inc. Announces CFO Transition
04:05pm, Thursday, 20'th Nov 2025
CELEBRATION, Fla., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a commercial-stage company focused on providing therapies for people living with
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Consensus Rating of “Moderate Buy” from Analysts
03:33am, Monday, 17'th Nov 2025
Shares of Zevra Therapeutics, Inc. (NASDAQ: ZVRA - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the eight brokerages that are covering the stock, Marketbeat.co
Zevra Therapeutics, Inc. (ZVRA) Q3 2025 Earnings Call Transcript
09:01pm, Wednesday, 05'th Nov 2025
Zevra Therapeutics, Inc. ( ZVRA ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Nichol Ochsner - Vice President of Investor Relations & Corporate Communications Neil McFarlan
Zevra Therapeutics (ZVRA) Reports Q3 Loss, Lags Revenue Estimates
06:50pm, Wednesday, 05'th Nov 2025
Zevra Therapeutics (ZVRA) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.69 per share a year ago.
Zevra Reports Third Quarter 2025 Financial Results and Corporate Update
04:05pm, Wednesday, 05'th Nov 2025
2025 EPS of $(0.01) Q3 2025 net revenue of $26.1 million , driven by MIPLYFFA ® net revenue of $22.4 million Company to host conference call and webcast TODAY, November 5, 2025 , at 4:30 p.m. ET CEL
Zevra Therapeutics to Participate in the Guggenheim Healthcare Innovation Conference
07:30am, Wednesday, 29'th Oct 2025
CELEBRATION, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with
Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call
07:30am, Monday, 27'th Oct 2025
- Company will host conference call at 4:30 p.m. ET on Wednesday, November 5, 2025 - Company will host conference call at 4:30 p.m. ET on Wednesday, November 5, 2025
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Average Recommendation of “Moderate Buy” from Brokerages
01:59am, Thursday, 23'rd Oct 2025
Shares of Zevra Therapeutics, Inc. (NASDAQ: ZVRA - Get Free Report) have received a consensus rating of "Moderate Buy" from the eight analysts that are presently covering the firm, Marketbeat.com repo
Zevra Therapeutics (ZVRA) Surges 12.3%: Is This an Indication of Further Gains?
09:56am, Thursday, 16'th Oct 2025
Zevra Therapeutics (ZVRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength d
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
05:51pm, Monday, 06'th Oct 2025
CELEBRATION, Fla., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with
Zevra Therapeutics (ZVRA) Soars 10.4%: Is Further Upside Left in the Stock?
06:25am, Thursday, 25'th Sep 2025
Zevra Therapeutics (ZVRA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price i
MIPLYFFA, the only therapy for Niemann-Pick disease type C (NPC) shown to stop disease progression at 12 months, has been administered to more than 270 patients, representing the largest data set of N
New data from pre-specified analysis shows patients on concomitant miglustat who switched from placebo to MIPLYFFA experienced a decline in annual disease progression
CELEBRATION, Fla., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with
